At Takeda we believe that no gastrointestinal (GI) disease that is life-limiting to patients should remain unnoticed or untreated. With nearly 30 years of experience in gastroenterology, we have made significant strides in developing treatments for patients in areas of high unmet need by using cutting-edge technologies to discover and develop a sophisticated range of medicines.
To make a real difference, we must truly understand how GI and liver diseases impact the everyday lives of patients. Routines are interrupted, symptom management takes precedence, and embarrassment can make the emotional pain just as present as the physical. Our approach is a simple one: if there is a need, we will seek to meet it; if there is a patient, we will strive to find a viable treatment solution for them.
Takeda’s world-class R&D team has an unwavering commitment and passion for developing innovative therapies. We collaborate in areas where patients’ needs are greatest, forming partnerships that will enable us to make a greater impact in GI and on patients’ lives - now and in the future. Together with researchers, patient groups and more, Takeda is working to advance scientific research and clinical medicine and will continue to expand our R&D in search of better disease management for all those affected by GI and liver diseases.
The following disease areas serve as Takeda’s core research focus in gastroenterology:
GI inflammation including advancement in inflammatory bowel diseases (ulcerative colitis and Crohn’s disease), and their associated complications such as perianal fistulas, short bowel syndrome and intestinal failure. This focus area also includes celiac disease and other gastrointestinal inflammatory diseases such as eosinophilic esophagitis.
GI motility including gastroparesis, nausea and vomiting, and rare enteric neuropathies.
Advanced liver diseases focusing on developing antifibrotics for diseases leading to late-stage liver fibrosis, complications of end-stage liver diseases, and select rare liver diseases.